Medications

Developing therapeutic peptides from scorpion venom

Canadian health and wellness company PreveCeutical Medical Inc. (PMI) has signed a research and option agreement with UniQuest, The University of Queensland's main commercialisation company, to develop stabilised natural ...

Inflammatory disorders

Tailored intervention in acute and chronic inflammation

Signal molecules called chemokines often work in tandem to recruit specific sets of immune cells to sites of tissue damage. A systematic analysis of their interactions by researchers from Ludwig-Maximilians-Universitaet (LMU) ...

Medical research

Team moves small-molecule drugs through blood-brain barrier

Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. ...

Immunology

Putting Lupus in permanent remission

Northwestern Medicine scientists have successfully tested a nontoxic therapy that suppresses Lupus in blood samples of people with the autoimmune disease.

Cardiology

New class of drug targets heart disease

(Edmonton) Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes.

Alzheimer's disease & dementia

New clues illuminate Alzheimer's roots

Scientists at Rice University and the University of Miami have figured out how synthetic molecules designed at Rice latch onto the amyloid peptide fibrils thought to be responsible for Alzheimer's disease. Their discovery ...

page 2 from 4